A Phase 2 interventional study of SOF/VEL and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 28 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-27.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.
Among the 174 studies testing ribavirin in Hepatitis C, this one is the 41st largest by enrollment, is one of 14 that started in 2016, is one of 47 in phase 2, and was the 164th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 61 · Phase 3 64 · Phase 4 44
First in 1997; this study’s year is marked. 14 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 78 across the 174 interventional studies. Of the 158 that completed or were terminated, 79 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 174 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
110 studies in Hepatitis C by Gilead Sciences: none open now, none under way, none of them phase 3. Of 109 finished, 79 (72%) have results posted.
Among the 110 studies in Hepatitis C by Gilead Sciences, this one is the 32nd largest by enrollment of the 97 interventional ones that give a count, is one of 13 that started in 2016, is one of 47 in phase 2, and was the 95th registered.
Gilead Sciences’s Hepatitis C studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 174 studies testing ribavirin in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 110 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and SOF/VEL FDC and ribavirin (RBV) for 12 weeks in participants with chronic genotype 3 hepatitis C virus (HCV) infection and compensated cirrhosis.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SOF/VEL FDC for 12 weeks
Drug: SOF/VEL
SOF/VEL FDC + RBV for 12 weeks
Drug: SOF/VEL · Drug: RBV
Drug pages: Sofosbuvir · Velpatasvir
400/100 mg FDC tablet administered orally once daily
Also known as: GS-7977/GS-5816, Epclusa®
RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12)
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
Time frame: Posttreatment Week 12
Percentage of Participants Who Permanently Discontinued Any Study Drug (Which Included SOF/VEL and RBV) Due to Any Adverse Event
Time frame: Posttreatment Week 12
Percentage of Participants Who Attain Sustained Virologic Response at 4 Weeks After Cessation of the Study Treatment Regimen (SVR4)
SVR4 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 4 weeks after stopping study treatment.
Time frame: Posttreatment Week 4
Percentage of Participants Who Have HCV RNA < LLOQ at Week 2
Time frame: Week 2
Percentage of Participants Who Have HCV RNA < LLOQ at Week 4
Time frame: Week 4
Percentage of Participants Who Have HCV RNA < LLOQ at Week 8
Time frame: Week 8
Percentage of Participants Who Have HCV RNA < LLOQ at Week 12
Time frame: Week 12
HCV RNA at Week 2
Time frame: Week 2
HCV RNA at Week 4
Time frame: Week 4
HCV RNA at Week 8
Time frame: Week 8
HCV RNA at Week 12
Time frame: Week 12
Change From Baseline in HCV RNA at Week 2
Time frame: Baseline; Week 2
Change From Baseline in HCV RNA at Week 4
Time frame: Baseline; Week 4
Change From Baseline in HCV RNA at Week 8
Time frame: Baseline; Week 8
Change From Baseline in HCV RNA at Week 12
Time frame: Baseline; Week 12
Percentage of Participants With Virologic Failure
Virologic failure was defined as * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ on 2 consecutive measurements while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement
Time frame: Up to Posttreatment Week 12
Participants were enrolled at study sites in Spain. The first participant was screened on 29 July 2016. The last study visit occurred on 27 October 2017.
| Milestone | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Started | 101 | 103 |
| Completed | 98 | 101 |
| Not completed | 3 | 2 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 |
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
| percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12) | 91.1 (83.8 to 95.8) | 96.1 (90.4 to 98.9) |
| percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Percentage of Participants Who Permanently Discontinued Any Study Drug (Which Included SOF/VEL and RBV) Due to Any Adverse Event | 1.0 | 1.9 |
SVR4 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 4 weeks after stopping study treatment.
| percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Percentage of Participants Who Attain Sustained Virologic Response at 4 Weeks After Cessation of the Study Treatment Regimen (SVR4) | 93.1 (86.2 to 97.2) | 97.1 (91.7 to 99.4) |
| percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Percentage of Participants Who Have HCV RNA < LLOQ at Week 2 | 51.0 (40.8 to 61.1) | 44.7 (34.9 to 54.8) |
| percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Percentage of Participants Who Have HCV RNA < LLOQ at Week 4 | 85.0 (76.5 to 91.4) | 90.3 (82.9 to 95.2) |
| percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Percentage of Participants Who Have HCV RNA < LLOQ at Week 8 | 99.0 (94.6 to 100.0) | 100.0 (96.4 to 100.0) |
| percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Percentage of Participants Who Have HCV RNA < LLOQ at Week 12 | 99.0 (94.6 to 100.0) | 100.0 (96.4 to 100.0) |
| log10 IU/mL | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| HCV RNA at Week 2 | 1.52 ± 0.513 | 1.47 ± 0.413 |
| log10 IU/mL | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| HCV RNA at Week 4 | 1.22 ± 0.257 | 1.19 ± 0.152 |
| log10 IU/mL | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| HCV RNA at Week 8 | 1.15 ± 0.040 | 1.15 ± 0.000 |
| log10 IU/mL | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| HCV RNA at Week 12 | 1.15 ± 0.018 | 1.15 ± 0.000 |
| log10 IU/mL | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Change From Baseline in HCV RNA at Week 2 | -4.67 ± 0.627 | -4.80 ± 0.580 |
| log10 IU/mL | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Change From Baseline in HCV RNA at Week 4 | -4.96 ± 0.641 | -5.09 ± 0.559 |
| log10 IU/mL | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Change From Baseline in HCV RNA at Week 8 | -5.04 ± 0.638 | -5.13 ± 0.565 |
| log10 IU/mL | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Change From Baseline in HCV RNA at Week 12 | -5.04 ± 0.640 | -5.13 ± 0.568 |
Virologic failure was defined as * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ on 2 consecutive measurements while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement
| percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Percentage of Participants With Virologic Failure | 5.9 | 1.9 |
Collected over Up to 12 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SOF/VEL | 0/101 (0%) | 4/101 (4%) | 24/101 (23.8%) |
| SOF/VEL + RBV | 0/103 (0%) | 2/103 (1.9%) | 55/103 (53.4%) |
| Event | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| PharyngotonsillitisInfections and infestations | 1/101 | 0/103 |
| Urinary tract infectionInfections and infestations | 1/101 | 0/103 |
| Accident at workInjury, poisoning and procedural complications | 1/101 | 0/103 |
| Limb injuryInjury, poisoning and procedural complications | 1/101 | 0/103 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/101 | 0/103 |
| Hepatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/101 | 1/103 |
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/101 | 1/103 |
| Event | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| AstheniaGeneral disorders | 12/101 | 28/103 |
| HeadacheNervous system disorders | 8/101 | 25/103 |
| InsomniaPsychiatric disorders | 1/101 | 12/103 |
| PruritusSkin and subcutaneous tissue disorders | 2/101 | 9/103 |
| Back painMusculoskeletal and connective tissue disorders | 7/101 | 4/103 |
| NauseaGastrointestinal disorders | 2/101 | 6/103 |
Safety Analysis Set: participants who took at least 1 dose of any study drug
| Age, Continuous(years) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| Mean | 51 ± 7.3 | 51 ± 7.6 | 51 ± 7.4 |
| Sex: Female, Male(Participants) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| Female | 26 | 16 | 42 |
| Male | 75 | 87 | 162 |
| Race/Ethnicity, Customized(Participants) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| White | 84 | 95 | 179 |
| Asian | 17 | 8 | 25 |
| Race/Ethnicity, Customized(Participants) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 10 | 19 |
| Not Hispanic or Latino | 92 | 93 | 185 |
| IL28B(Participants) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| CC | 64 | 53 | 117 |
| Non-CC | 36 | 50 | 86 |
| Missing | 1 | 0 | 1 |
| HCV RNA(log10 IU/mL) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| Mean | 6.2 ± 0.64 | 6.3 ± 0.56 | 6.2 ± 0.60 |
| HCV RNA Category(Participants) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| < 800,000 IU/mL | 32 | 24 | 56 |
| ≥ 800,000 IU/mL | 69 | 79 | 148 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Jul 2016 to primary completion in Oct 2017, 14 months.
Results were first posted in Oct 2018, 1 year after primary completion.
Of 48 industry-sponsored phase 2 interventional studies under Hepatitis C, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 26. This study's 14 months is below that.
Counting every sponsor, half of 61 studies reached it within 19 months; a quarter within 13 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribavirin